NCT03213691
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: RAS, RAF, NF1/2, GNA
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Months to 21 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Patient must have enrolled on the Pediatric MATCH Screening Trial (NCT03155620)
Exclusions: Patients over the age of 21
https://ClinicalTrials.gov/show/NCT03213691